Free shipping — the threshold depends on the destination country, confirmed at checkout.

    Research Use Only (RUO). For laboratory research only. Not for human or veterinary use.

    Avenor Peptides
    Research Use Only (RUO):Research classification with product and batch documentation where available.
    Orforglipron 6 mg - Avenor Peptides

    Weight & Metabolism

    Orforglipron

    Strength: 6 mg

    Orforglipron is studied around body weight and blood sugar, like the GLP-1 peptides — with one difference: it is not a peptide and not an injection. It is a pill.

    €190,00
    In stock
    1

    The more products, the bigger the discount

    2 → −5%
    3 → −8%
    4 → −11%
    5+ → −15%
    across your whole basket, automatically
    Batch documentationShips from Greece

    Free shipping: Greece from €50, Cyprus and Bulgaria from €100, France, Germany, Italy, Belgium, Netherlands and Spain from €200. Details

    This product is intended exclusively for laboratory research use. It is not intended for human consumption, diagnosis, treatment, or prevention of disease.

    Product information

    FormOral form
    Strength6 mg
    SKUAVR-ORFORGLIPRON-6MG
    Stock statusIn stock
    COA / BatchSee the documentation state below
    StorageRefer to the label and available documentation details.
    Packaging / shippingControlled shipping preparation according to the available SKU variant.

    Documentation on request

    There is no published document for this specific SKU variant at the moment.

    Contact us about documentation

    Research overview

    What it is researched for

    Research focuses on topics such as:

    • body-weight regulation
    • appetite and feeling full
    • blood-sugar levels

    Areas of research — not a promise of results.

    How this category is positioned

    It presses the same "switch" as Semaglutide (GLP-1), but it is built differently: a small molecule instead of a peptide. That is why it is taken by mouth.

    Documentation & COA

    Batch documentation and COA, where available, are linked to the specific product batch and SKU.

    This product is intended exclusively for laboratory research use. It is not intended for human consumption, diagnosis, treatment, or prevention of disease.

    Product profile

    1 nM

    inhibition constant (Ki) at the human GLP-1 receptor

    25-68 hours

    half-life recorded in Phase 1 studies

    3,127

    participants in the ATTAIN-1 Phase 3 trial

    ≥98%

    purity by HPLC

    Research context

    What it is

    Orforglipron is not a peptide. It is a small synthetic molecule that mimics a gut hormone.

    Every earlier molecule in this class was a peptide — large, fragile, hard to survive the stomach.

    This one is taken by mouth, once a day.

    The technical detail

    A small-molecule, non-peptide agonist of the GLP-1 receptor, from Eli Lilly.

    How it works

    It presses the same switch as the injectable GLP-1 molecules.

    It regulates insulin, slows how fast the stomach empties, and talks to the brain about fullness.

    The difference is not the mechanism. It is that a small molecule survives digestion without an injection and without the strict rules that peptide pills demand.

    The technical detail

    Small-molecule agonism of GLP-1R allows oral bioavailability without the formulation constraints of a peptide.

    What the studies showed

    Two large phase 3 trials, in 2025 and 2026.

    Both in adults with type 2 diabetes.

    1,613

    ATTAIN-2, Lancet 2025

    −9.6%

    weight at 72 weeks

    962

    ACHIEVE-2, Lancet 2026

    −1.56%

    HbA1c at 40 weeks

    In ATTAIN-2, mean weight loss on the highest arm was −9.6% at 72 weeks, against −2.5% on placebo.

    How it compares

    The 2026 ACHIEVE-2 trial put it directly against dapagliflozin, an established oral drug for diabetes.

    −1.56%

    Orforglipron

    vs

    −0.81%

    Dapagliflozin

    The drop in HbA1c was nearly double in favour of orforglipron. That is a measurement from a direct comparison, not an estimate.

    The technical detail

    Welch et al., Lancet 2026 (ACHIEVE-2): non-inferiority was met and superiority shown; gastrointestinal events were more frequent than with dapagliflozin.

    Laboratory use

    Used in a controlled laboratory setting for in vitro binding and activation studies at the GLP-1 receptor, for biased-signalling analysis (cAMP generation versus beta-arrestin recruitment), for comparative work between non-peptide and peptide agonists, for selectivity profiling against other class B receptors, and for identity and purity confirmation by chromatographic and mass spectrometric methods.

    Research Use Only. For laboratory research exclusively. Not intended for human or veterinary use, diagnosis, treatment, or disease prevention. The clinical data referenced concern a pharmaceutical product under development and do not constitute an indication for use of this material; they do not transfer to research-grade material and are not a claim of efficacy or safety for it. The mg figures cited serve solely as clinical trial arm labels and are not guidance.

    Structural data

    Class
    Non-peptide (small-molecule) GLP-1 receptor agonist — not a peptide
    Type of agonism
    Partial agonist with biased signalling — favours G protein activation over beta-arrestin recruitment (Kawai et al., 2020)
    Binding affinity
    Ki = 1 nM at the human GLP-1 receptor (Sloop et al., 2024)
    Development codes
    LY3502970 and OWL833
    Binding site
    A distinct pocket in the upper helical bundle of the receptor — engaging the extracellular domain (ECD), extracellular loop 2, and transmembrane helices 1, 2, 3 and 7
    Species selectivity
    Interaction with Trp33 of the extracellular domain, present only in primates, determines species-selective activity
    Receptor selectivity
    Highly selective against other class B G protein-coupled receptors (GPCRs)
    Half-life
    25-68 hours in Phase 1 study participants — compatible with once-daily oral dosing
    Food effect
    AUC and Cmax fell by 17.6-23.7% in the fed versus fasted state — a difference the authors judged not clinically meaningful (Ma et al., 2024)
    Product form
    Oral capsule in sealed packaging — no reconstitution or solvent required
    Purity
    ≥98% (HPLC) — supplied with CoA

    Comparison

    Feature comparison

    FeatureOrforglipron (this product)SemaglutideTirzepatide
    Molecule typeNon-peptide small moleculeSynthetic 31-amino-acid peptideSynthetic 39-amino-acid peptide
    Route used in the trialsOral, no injectionSubcutaneous injection (an oral form also exists, with water and food restrictions)Subcutaneous injection
    Catalogue product formCapsule — no reconstitution neededLyophilized powder in a vialLyophilized powder in a vial
    Receptors activatedONE: GLP-1 (partial agonist)ONE: GLP-1 (full agonist)TWO: GIP + GLP-1
    Food/water restrictions in the trialsNo fasting requirement in the Phase 2 and Phase 3 protocolsThe oral form requires fasting and limited waterNot applicable — injectable
    StorageRoom temperature, dry environmentRefrigeratedRefrigerated
    Head-to-head trialNon-inferior and superior to oral semaglutide for HbA1c change in ACHIEVE-3 (Rosenstock et al., 2026)The comparator in ACHIEVE-3No published Phase 3 head-to-head against orforglipron
    Maturity of the evidenceCompleted Phase 3 trials (ATTAIN, ACHIEVE) — in regulatory developmentApproved pharmaceutical product with a completed Phase 3 programmeApproved pharmaceutical product with a completed Phase 3 programme

    Storage & handling

    • Capsules are stored at room temperature — no refrigeration or freezing required.
    • The product is ready as supplied: no reconstitution, solvent, bacteriostatic water, or any preparation step is involved.
    • Store in a dry environment, away from moisture and heat sources.
    • Keep in the original sealed packaging, protected from light, until the point of laboratory use.
    • No freeze–thaw cycles apply; the solid form does not require that kind of handling.
    • Handle using standard laboratory practice and appropriate personal protective equipment.
    • Keep away from children and out of food preparation areas.

    Documentation

    • Certificate of Analysis (CoA) per batch, with date and lot number.
    • Purity analysis by HPLC — specification ≥98%.
    • Identity and molecular weight confirmation by mass spectrometry.
    • Research Use Only (RUO) declaration on the packaging.
    • Documents available on request for the specific batch of each order.

    References

    References & documentation

    1. 1.Kawai T. et al. (2020). Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proc Natl Acad Sci U S A, 117(47), 29959-29967.
    2. 2.Pratt E. et al. (2023). Orforglipron (LY3502970), a novel, oral non-peptide GLP-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants. Diabetes Obes Metab.
    3. 3.Pratt E. et al. (2023). Orforglipron (LY3502970), a novel, oral non-peptide GLP-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes. Diabetes Obes Metab.
    4. 4.Frías J.P. et al. (2023). Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet.
    5. 5.Wharton S. et al. (2023). Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med.
    6. 6.Karakasis P. et al. (2023). Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials. Metabolism.
    7. 7.Ma X. et al. (2024). Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist. Diabetes Ther.
    8. 8.Sloop K.W. et al. (2024). The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron. Sci Transl Med.
    9. 9.Rosenstock J. et al. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1). N Engl J Med.
    10. 10.Wharton S. et al. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med.
    11. 11.Horn D.B. et al. (2025). Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet.
    12. 12.Rosenstock J. et al. (2026). Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet, 407(10534), 1147-1160.
    13. 13.Giorgino F. et al. (2026). Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial. JAMA.
    14. 14.Aronne L.J. et al. (2026). Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med, 32(7), 2679-2687.
    15. 15.Panou T. et al. (2025). Orforglipron in type 2 diabetes mellitus and obesity: an overview. Expert Rev Clin Pharmacol.

    Category comparison

    Not sure which GLP-1 to choose?

    See the comparison

    Product information

    Frequently asked questions

    Why does this molecule not need an injection?
    Because it is not a peptide. Peptides are amino acid chains that digestive enzymes break down before absorption can occur, which is why most molecules in this class are studied by subcutaneous injection. Orforglipron is a synthetic small molecule with no peptide backbone, so there is no chain for the stomach to degrade. The Phase 1 studies by Pratt and colleagues (2023) recorded a half-life of 25-68 hours after oral administration — long enough to support once-daily use.
    How does it differ from the oral form of semaglutide?
    Oral semaglutide is still a peptide and works around the absorption problem with an enhancer, which is why it requires an empty stomach and minimal water. Orforglipron does not face that constraint. Ma and colleagues (2024) measured a 17.6-23.7% drop in exposure in the fed state — a difference they judged not clinically meaningful — and the Phase 2 and Phase 3 protocols imposed no food or water restriction whatsoever.
    What does "partial agonist with biased signalling" mean?
    Partial means it switches the receptor on but not to the full extent the native GLP-1 hormone does. Biased signalling means that of the two pathways running from the receptor, it favours one: G protein activation over recruitment of beta-arrestin, the protein that normally withdraws the receptor from the cell surface. This was established by Kawai and colleagues (PNAS, 2020) and confirmed by Sloop and colleagues (2024).
    What did the ATTAIN trials show?
    ATTAIN-1 (Wharton et al., New England Journal of Medicine, 2025) enrolled 3,127 participants with obesity and without diabetes over 72 weeks: mean weight change of -11.2% in the highest arm against -2.1% on placebo, with 18.4% of that arm recording a reduction of 20% or more. ATTAIN-2 (Horn et al., Lancet, 2025), in 1,613 participants with both obesity and type 2 diabetes, recorded -9.6% versus -2.5%.
    What did the ACHIEVE trials show?
    ACHIEVE-1 (Rosenstock et al., New England Journal of Medicine, 2025) in 559 participants with early type 2 diabetes recorded glycated haemoglobin reductions of up to 1.48 percentage points at 40 weeks, with no episodes of severe hypoglycaemia. ACHIEVE-5 (Giorgino et al., JAMA, 2026) in 546 participants already receiving insulin glargine found no increase in clinically significant hypoglycaemia risk.
    Is there a head-to-head against a peptide agonist?
    Yes. ACHIEVE-3 (Rosenstock et al., Lancet, 2026) randomised 1,698 participants to orforglipron or oral semaglutide over 52 weeks. The non-peptide molecule met non-inferiority and then superiority, with glycated haemoglobin change of -1.91% in its highest arm against -1.47% for the peptide. Earlier, in Phase 2 (Frías et al., Lancet, 2023), the active comparator was injectable dulaglutide at -1.10% against up to -2.10%.
    What negative findings appear in the literature?
    Several, and they are not minor. In ACHIEVE-3, gastrointestinal events were more frequent with orforglipron (58-59%) than with oral semaglutide (37-45%), discontinuations due to adverse events roughly doubled (9-10% versus 4-5%), and the mean rise in pulse rate was larger (3.7-4.7 versus 1.0-1.5 bpm); four deaths were recorded, two in each treatment family. The meta-analysis by Karakasis and colleagues (Metabolism, 2023) found significantly raised odds of gastrointestinal events and of discontinuation, and in the Phase 2 obesity study discontinuation reached 17%.
    What are the limits of the available data?
    Three, mainly. Time horizon: the largest published trial ran 72 weeks and no cardiovascular outcomes study has reported. Trial design: ATTAIN-MAINTAIN (Aronne et al., Nature Medicine, 2026) explicitly lists the absence of a continued-injectable comparator arm and its one-year duration as limitations. And tolerability, as described above. The molecule is also still in regulatory development — this is not a compound with decades of clinical history behind it.
    Can it be used by humans or animals?
    No. The product is supplied exclusively for laboratory research. It is not intended for human or veterinary use, nor for in vivo application outside a controlled laboratory setting. No administration or dosing guidance is provided, and the fact that the form is a capsule changes nothing about that.
    How is it stored, and does it need reconstitution?
    No reconstitution is needed. Unlike the lyophilized peptides in the catalogue, which arrive as powder in a vial and require refrigeration and a solvent, the capsule is stored at room temperature in a dry environment, in its original sealed packaging. No freeze–thaw cycles apply.